Back to Freepaper Session

IOP after anterior chamber phakic IOL implantation

Session Details

Session Title: Phakic IOL Implantation I

Session Date/Time: Tuesday 08/10/2013 | 14:00-16:00

Paper Time: 15:42

Venue: Main Lecture Hall (Ground Floor)

First Author: : M.Freitas PORTUGAL

Co Author(s): :    A. Marinho              

Abstract Details

Purpose:

To evaluate the evolution of IOP after Artiflex phakic IOL and Acrysof Cachet phakic IOL implantation. To evaluate the risk of OHT/glaucoma peri and post operative and which mechanisms could be envolved.

Setting:

Hospital Arrįbida, Porto Portugal

Methods:

There are two groups of patients implanted with two kinds of anterior chamber phakic IOL. All the eyes were implanted by the same surgeon (A. Marinho). Group A: 88 eyes with myopia were implanted with Artiflex phakic IOL between 2005 -2007 and the results consider a follow-up minimum of 60 months. Oral steroids were prescribed during 9 days and topic steroids during 4 to 6 weeks. Group B: 120 eyes with myopia were implanted with Acrysof Cachet phakic IOL between 2008-2012 and the results consider a follow-up minimum of 6 months. Topic steroids were prescribed during 2 weeks. In Group B the eyes were then divided in three groups according to IOL compression (difference between the size of IOL and anterior chamber diameter): Group B.1.: compression < 1mm; Group B.2.: compression = 1mm and Group B.3.: compression > 1mm. IOP was measured by Goldmann applanation tonometer. Before surgery, 1st day, 1,3, 12, 18, 36 and 60th months IOP was evaluated.

Results:

Group A: The mean IOP was 15.57±2.10mmHg, before surgery and1st day, 1, 12, 36 and 60th months, respectively: 16.00±2.30; 17.70± 5.11; 15.93±2.07; 14.66±1.97 and 16.32±3.77 mmHg. None developed pupillary block, OHT related with viscoelastic, pigment dispersion syndrome or angle closure OHT. 10 eyes (11.36%) developed IOP>21mmHg after steroids treatment. All OHT but three eyes normalised after stopping steroids treatment. Those eyes are at the moment controlled with drops. No glaucoma surgery was needed. Group B: Considering all eyes, the mean IOP was 14.33 ± 2.9; 14.34 ± 2.06; 14.47±2.05; 14.64±1.65 and 14.92±1.92, before surgery, at day one, 1, 3 and 18 months, respectively. In Group B.1., the mean IOP was 15.38±1.46; 15.16± 1.54; 15.33±2.06; 14.78±1.30 and 13.67±3.21, before surgery, at day one, 1, 3 and 18 months, respectively. In Group B.2., the mean IOP was 14.70 ±1.83; 14.88±2.01; 15.03±2.00; 14.88±1.53 and 15.00±1.58, before surgery, at day one, 1, 3 and 18 months, respectively. In Group B.3., the mean IOP was 13.93 ±2.37; 13.81±2.12; 13.94±1.95; 14.08±1.85 and 14.82±2.21, before surgery, at day one, 1, 3 and 18 months, respectively. These differences are not statistically significant. None developed pupillary block, OHT related with viscoelastic material, pigment dispersion syndrome or angle closure OHT.

Conclusions:

Artiflex phakic IOL are safe in concerning IOP. Acrysof Cachet phakic IOL implantation does not change IOP throughout the follow-up and the IOL compression does not influence the IOP in this series.

Financial Interest:

... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented